News Release Details

SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting an HIV Activism Digital Summit on Friday, December 13, 2019 from 3 p.m. to 5 p.m. Eastern. The summit will feature commentary by prominent HIV advocates Bruce Richman, Maria Mejia, and Ken Williams (AKA Ken Like Barbie), as well as by Jaguar CEO Lisa Conte and Napo employee Brian Coppedge. Josh Robbins will serve as the host of the event, which will be the first completely digital, activist-led virtual program in the HIV community and is intended to continue fostering the important conversations needed to address living with HIV and living with comorbidities like HIV-associated diarrhea. To sign up for free to view the live summit, visit https://napopharma.com/summit. The discussion can be viewed on Napo's Facebook page (facebook.com/napopharma), Napo's website (https://napopharma.com/summit) and on Crowdcast (https://www.crowdcast.io/e/hivsummit).

"We are very proud that Napo's first HIV Activism Digital Summit will feature such extraordinary activists," Robbins commented. "These powerhouse advocates comprise an HIV activism dream team because of their incredible work that continues to lead to real change for people living with HIV."

Richman, who will serve as the summit's keynote speaker, is the founding executive director of the Prevention Access Campaign and the "Undetectable = Untransmittable (U=U)" campaign. He has worked in global philanthropy for over two decades developing foundations, cause-marketing and grantmaking programs, social marketing campaigns, and interventions on a range of issues including HIV stigma and prevention. Richman was honored for his work with U=U as Healthline's HIV influencers "2017 Person of the Year" and named Plus Magazine "#1 Most Amazing HIV+ People of 2018". He received his Ed.M. in Administration, Planning & Social Policy from Harvard Graduate School of Education and his J.D. from Harvard Law School.

Diagnosed with HIV in 1991, Mejia has since become a tireless advocate for people living with HIV. She is a global ambassador for The Well Project, an international nonprofit for women and girls with HIV, the founder of two international Facebook support groups, an HIV counselor, and co-author of From a Warrior's Passion and Pain, a real-life account of her battle with HIV. She has spoken at national and international conventions and been featured in numerous campaigns including the Greater Than AIDS campaign on IPV, HIV and women, the Centers for Disease Control's campaign, "Let's Stop HIV Together", The Stigma Project and the Office of Women's Health's National Women and Girls HIV/AIDS Awareness Day.

Williams, an activist and advocate living with HIV, is the creative force behind the award-winning video blog Ken Like Barbie. He has collaborated on projects with the Black AIDS Institute, the Centers for Disease Control and Prevention, Greater Than AIDS, and HIV.gov (where he's a regular blogger for the Black Voices project).

Coppedge, a specialty territory manager at Napo, has spent twenty years working to meet the health needs of people living with HIV/AIDS. Prior to joining Napo, he spent 11 years with Bristol-Myers Squibb, serving in roles involving both patient and community affairs management and sales. Coppedge is also an experienced health educator and the former executive director of a Seattle-based HIV/AIDS non-profit.

Robbins is an HIV activist, blogger, writer, social media marketer, and a consultant to Napo. He was recently honored with the National Lesbian & Gay Journalist Association "Excellence in Journalism: Blogging Award". He is a GLAAD-nominated blogger, a keynote and university speaker on sexual health and overcoming difficulty to live well, and he gave a TEDx Talk on how patients use social media to maintain healthy lifestyles despite chronic conditions.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi^® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

About Mytesi^®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Napo will host an HIV Activism Digital Summit December 13, 2019. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.